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In this issue of Chemistry & Biology, Hari and colleagues show that two positions in kinase active sites,
including the well-known ‘‘gatekeeper’’ residue, regulate ‘‘in’’ versus ‘‘out’’ conformations of the conserved
‘‘DFG’’ motif. These findings suggest yet another role for the gatekeeper residue.The impact of the kinase conformational
state on inhibitor potency and selectivity
is an important but poorly understood
problem in kinase inhibitor drug discov-
ery. The breakthrough drug imatinib
showed us several years ago that the
plasticity of kinase structure can enable
the development of selective kinase in-
hibitors despite the high sequence con-
servation within this large protein family.
Imatinib is classified as a ‘‘type II’’ kinase
inhibitor because it contacts both the ATP
cofactor binding site and an adjacent
‘‘allosteric’’ site available only when the
kinase assumes a catalytically inactive
conformation where the ‘‘Asp-Phe-Gly
(DFG)’’ motif at the N terminus of the acti-
vation loop is flipped ‘‘out’’ relative to its
conformation in the active state (‘‘in’’)
(Figure 1B) (Nagar et al., 2002). In
contrast, type I inhibitors including
VX-680 (and dasatinib) bind at the ATP
site but do not penetrate the allosteric
pocket and therefore do not depend on
specific kinase conformations for binding
(Figure 1A). Type II inhibitors are generally
more selective than type I inhibitors
across the enormous human kinome
(518 members) (Davis et al., 2011), but
the reasons for this selectivity advantage
are not well understood. Are the addi-
tional contacts made by type II inhibitors
in the less well-conserved allosteric
pocket critical for selectivity? Is it that
many kinases do not adopt, or only poorly
adopt, the ‘‘DFG-out’’ conformation
required for type II inhibitor binding? Or
is it some of both? The results presented
by Hari et al. (2013) in this issue of Chem-
istry & Biology address this question and
suggest that inherent differences in the
ability of kinases to adopt the DFG-out
conformation can indeed contribute to
the selectivity of type II inhibitors.Based upon the mutagenesis data pre-
sented, the authors propose that two
residues influence the ability of kinases
to adopt a DFG-out conformation
(Figure 1). One of these is perhaps the
best studied residue in kinases, known
as the ‘‘gatekeeper’’, so named because
kinases typically have bulky amino acids
occupying this position, and mutation at
this position to Gly or Ala can enable
molecules access to a deeper hydropho-
bic pocket. Bishop et al. (2000) previ-
ously exploited this concept to generate
mutant alleles of kinases that could be
selectively inhibited by compounds that
require access to the hydrophobic
pocket to stably bind kinases and inhibit
kinase activity. In a similar manner, Ke-
van Shokat’s group demonstrated that
direct substrates of these mutant alleles
can be identified with the use of a bulky
ATP analog, which can efficiently act as
a cofactor for the modified kinase (Allen
et al., 2007). The importance of this res-
idue to pharmacology was first hinted
at in a seminal study by John Kuriyan’s
group, which provided the first evidence
that the prototypic small molecule tyro-
sine kinase inhibitor imatinib binds to
ABL kinase in an inactive, DFG-out
(type II) manner (Schindler et al., 2000).
Moreover, Kuriyan speculated that the
gatekeeper Thr in ABL was critical for
the ability of imatinib to bind due to its
contribution of an important stabilizing
H-bond (Schindler et al., 2000). It was
therefore scientifically gratifying when
Charles Sawyers’ group found that
several patients with loss of response
to imatinib had evolved bulky Ile substi-
tutions at this residue, which not only
destroyed the ability to establish an
H-bond, but presumably further contrib-
uted to a high degree of imatinib resis-Chemistry & Biology 20, June 20, 2013tance as a result of steric clash (Gorre
et al., 2001). This mutation, known
commonly as breakpoint cluster region-
ABL/T315I, is highly resistant not only
to imatinib, but also to three other
approved second generation ABL inhibi-
tors: dasatinib, bosutinib (type I inhibi-
tors), and nilotinib (a type II inhibitor).
Only recently has a clinically effective ki-
nase inhibitor that retains activity against
this mutant been identified and approved
(ponatinib, a type II inhibitor). Impor-
tantly, among multiple kinases that have
been effectively targeted clinically (KIT,
PDGFRA, EGFR, EML4-ALK, and FLT3),
gatekeeper mutations are commonly
found to confer resistance. Notably, for
EGFR, the gatekeeper T790M mutation
has been demonstrated to confer resis-
tance to EGFR inhibitors not for steric rea-
sons, but due to an increased affinity for
ATP (Yun et al., 2008). Interestingly, there
is evidence that gatekeeper residue
substitutions can have effects on kinase
activation. Azam and colleagues demon-
strated that select gatekeeper substitu-
tions of ABL and SRC kinases can be
activating, and proposed a mechanism
whereby the hydrophobic spine in this
region of the kinase is stabilized by
these substitutions (Azam et al., 2008).
Additionally, the identity of the gatekeeper
residue can influence substrate specificity
(Skaggs et al., 2006).
In the accompanying study by Hari
et al. (2013), yet another activity has
been ascribed to the gatekeeper residue:
the ability (along with the residue referred
to as xDFG immediately N-terminal to the
conserved Asp-Phe-Gly [DFG] motif at
the base of the activation loop) to influ-
ence the capacity of kinases to sample
a DFG-out conformation. Should these
predictions hold true across the entireª2013 Elsevier Ltd All rights reserved 745
Figure 1. DFG-In and -Out Conformations of Inhibitor-Bound ABL
(A) Cocrystal structure of the type I inhibitor VX-680 (gray) bound to ABL (cyan)
(Young et al., 2006). The activation loop (yellow) adopts the active DFG-in
conformation. The gatekeeper and xDFG residues shown by Hari et al.
(2013) to govern DFG conformation are indicated by orange and magenta cir-
cles, respectively.
(B) Cocrystal structure of the type II inhibitor imatinib (gray) bound to ABL
(cyan) (Nagar et al., 2002). The activation loop adopts the inactive-DFG-out
conformation exposing the allosteric pocket (transparent, yellow circle) occu-
pied by imatinib. In (A), this pocket is occupied by the DFGmotif, which adopts
the ‘‘in’’ conformation.
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assumed that perhaps the
majority of kinases will be
difficult to selectively target
with type II inhibitors.
Whereas some compelling
data to support the impor-
tance of these residues in
kinase conformation are pre-
sented in the manuscript, it
appears that there will likely
be other contextual influ-
ences as well. For example,
the authors provide evidence
that mutating Leu to Cys at
xDFG prevents JNK3 from
binding to their type II confor-
mation indicator probe,
thereby suggesting that Cys
immediately N-terminal to
DFG destabilizes the DFG-
out conformation. However,
FLT3 contains a Cys at this
position and clearly has the
ability to access a DFG-out
conformation, as evidenced
by the clinically active type II
FLT3 inhibitors such as qui-
zartinib, sorafenib, and pona-
tinib. Furthermore, examplesof nonselective type II inhibitors have
been reported, including AST-487 and
EXEL-2880, which have low nM activity
on many kinases, including p38-delta
(Davis et al., 2011), which was shown
by Hari et al. (2013) to be resistant to
other type II inhibitors unless mutated at
the gatekeeper position. It will therefore
be important to assess the validity of the
authors’ predictions in the context of
what is currently known about the ability
of members of the human kinome to
adopt a DFG-out conformation. Type I
inhibitors, which are generally not sensi-746 Chemistry & Biology 20, June 20, 2013 ªtive to the DFG conformation, should
also be tested against the reported
mutant ‘‘type II-sensitive’’ and wild-type
‘‘type II-insensitive’’ kinases to further
establish the identified residues as
regulators of DFG conformation. Never-
theless, the study provides a welcome
initial framework for thinking about
intrinsic factors that govern kinase
conformation, and the identified mutants
will be valuable tools for future studies
aimed at understanding how inhibitor
type impacts potency and selectivity
in vitro and in vivo.2013 Elsevier Ltd All rights reservedREFERENCES
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